JP2020537497A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537497A5 JP2020537497A5 JP2020514269A JP2020514269A JP2020537497A5 JP 2020537497 A5 JP2020537497 A5 JP 2020537497A5 JP 2020514269 A JP2020514269 A JP 2020514269A JP 2020514269 A JP2020514269 A JP 2020514269A JP 2020537497 A5 JP2020537497 A5 JP 2020537497A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleic acid
- acid conjugate
- acid molecule
- exon
- conjugate according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091033319 polynucleotide Proteins 0.000 claims 35
- 102000040430 polynucleotide Human genes 0.000 claims 35
- 108020004999 messenger RNA Proteins 0.000 claims 10
- 102000007238 Transferrin Receptors Human genes 0.000 claims 6
- 108010033576 Transferrin Receptors Proteins 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 101150015424 dmd gene Proteins 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- 108010069091 Dystrophin Proteins 0.000 claims 2
- 102100024108 Dystrophin Human genes 0.000 claims 2
- 108091027305 Heteroduplex Proteins 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 108091093037 Peptide nucleic acid Proteins 0.000 claims 1
- 102000004357 Transferases Human genes 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023118556A JP7635307B2 (ja) | 2017-09-22 | 2023-07-20 | エクソンスキッピングを誘発する核酸ポリペプチド組成物と方法 |
| JP2025021008A JP7880452B2 (ja) | 2017-09-22 | 2025-02-12 | エクソンスキッピングを誘発する核酸ポリペプチド組成物と方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762561939P | 2017-09-22 | 2017-09-22 | |
| US62/561,939 | 2017-09-22 | ||
| US201862696766P | 2018-07-11 | 2018-07-11 | |
| US62/696,766 | 2018-07-11 | ||
| PCT/US2018/052289 WO2019060775A1 (en) | 2017-09-22 | 2018-09-21 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND EXON JUMP INDUCTION METHODS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023118556A Division JP7635307B2 (ja) | 2017-09-22 | 2023-07-20 | エクソンスキッピングを誘発する核酸ポリペプチド組成物と方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020537497A JP2020537497A (ja) | 2020-12-24 |
| JP2020537497A5 true JP2020537497A5 (enExample) | 2021-10-21 |
Family
ID=65810507
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514269A Pending JP2020537497A (ja) | 2017-09-22 | 2018-09-21 | エクソンスキッピングを誘発する核酸ポリペプチド組成物と方法 |
| JP2023118556A Active JP7635307B2 (ja) | 2017-09-22 | 2023-07-20 | エクソンスキッピングを誘発する核酸ポリペプチド組成物と方法 |
| JP2025021008A Active JP7880452B2 (ja) | 2017-09-22 | 2025-02-12 | エクソンスキッピングを誘発する核酸ポリペプチド組成物と方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023118556A Active JP7635307B2 (ja) | 2017-09-22 | 2023-07-20 | エクソンスキッピングを誘発する核酸ポリペプチド組成物と方法 |
| JP2025021008A Active JP7880452B2 (ja) | 2017-09-22 | 2025-02-12 | エクソンスキッピングを誘発する核酸ポリペプチド組成物と方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20200282074A1 (enExample) |
| EP (2) | EP3684376A4 (enExample) |
| JP (3) | JP2020537497A (enExample) |
| KR (2) | KR102805405B1 (enExample) |
| CN (1) | CN111770757A (enExample) |
| AU (2) | AU2018335880B2 (enExample) |
| CA (1) | CA3075425A1 (enExample) |
| IL (2) | IL326219A (enExample) |
| MA (1) | MA50269A (enExample) |
| MX (1) | MX2020003130A (enExample) |
| SG (1) | SG11202002517RA (enExample) |
| WO (1) | WO2019060775A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| KR20240172236A (ko) | 2017-01-06 | 2024-12-09 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법 |
| GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
| CN118638787A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| EP3735252A4 (en) * | 2018-01-04 | 2021-10-06 | Avidity Biosciences, Inc. | HETERODUPLEX NUCLEIC ACID MOLECULES AND USES THEREOF |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2020219820A1 (en) | 2019-04-25 | 2020-10-29 | Avidity Biosciences, Inc. | Nucleic acid compositions and methods of multi-exon skipping |
| US20220282247A1 (en) * | 2019-08-02 | 2022-09-08 | Research Institute At Nationwide Children's Hospital | Exon 44-targeted nucleic acids and recombinant adeno-associated virus comprising said nucleic acids for treatment of dystrophin-based myopathies |
| CN114929336A (zh) * | 2019-09-19 | 2022-08-19 | 阿尔奈科学有限责任公司 | 用于调节基因剪接的化合物和方法 |
| EP4079329A4 (en) * | 2019-12-19 | 2024-04-17 | Nippon Shinyaku Co., Ltd. | ANTISENSE NUCLEIC ACID ENABLING EXON SKIPPING |
| CN122124274A (zh) * | 2020-01-10 | 2026-06-02 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗面肩肱型肌营养不良的用途 |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| TW202144572A (zh) | 2020-03-19 | 2021-12-01 | 美商亞維代堤生物科學公司 | 治療臉肩胛肱骨肌肉失養症之組合物及方法 |
| KR102927945B1 (ko) | 2020-03-27 | 2026-02-23 | 어비디티 바이오사이언시스 인크. | 근이영양증의 치료용 조성물 및 방법 |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| MX2023000984A (es) * | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| KR20230117182A (ko) * | 2020-12-04 | 2023-08-07 | 다인 세라퓨틱스, 인크. | 항체-올리고뉴클레오티드 복합체 및 그의 용도 |
| WO2022232478A1 (en) | 2021-04-30 | 2022-11-03 | Sarepta Therapeutics, Inc. | Treatment methods for muscular dystrophy |
| US11655473B2 (en) * | 2021-05-28 | 2023-05-23 | Novo Nordisk A/S | Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (MARC1) expression |
| JP2024525613A (ja) * | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US20240318176A1 (en) * | 2021-07-09 | 2024-09-26 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2023026994A1 (ja) * | 2021-08-21 | 2023-03-02 | 武田薬品工業株式会社 | ヒトトランスフェリンレセプター結合ペプチド－薬物コンジュゲート |
| EP4401792A4 (en) | 2021-09-16 | 2025-12-03 | Avidity Biosciences Inc | COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY |
| MX2024006612A (es) * | 2021-12-03 | 2024-06-12 | Quralis Corp | Oligonucleotidos antisentido de cambio de empalme con estructuras quimicas modificadas. |
| KR20240125036A (ko) * | 2021-12-23 | 2024-08-19 | 마이레큘, 인크. | 폴리뉴클레오타이드의 전달을 위한 조성물 |
| CA3248917A1 (en) * | 2022-01-20 | 2023-07-27 | Bolden Therapeutics, Inc. | OLIGONUCLEOTIDES TARGETING MUSK |
| EP4215614A1 (en) | 2022-01-24 | 2023-07-26 | Dynacure | Combination therapy for dystrophin-related diseases |
| EP4493693A1 (en) | 2022-03-17 | 2025-01-22 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
| US12071621B2 (en) * | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| WO2024101349A1 (ja) | 2022-11-07 | 2024-05-16 | 株式会社日本触媒 | 可溶化ポリマーの製造方法および吸水性樹脂の製造方法 |
| WO2024197302A1 (en) * | 2023-03-23 | 2024-09-26 | Yale University | Compositions and methods for delivering antibody oligonucleotide conjugates for exon skipping |
| CN116381125A (zh) * | 2023-06-05 | 2023-07-04 | 迦进生物医药(上海)有限公司 | 评估与蛋白偶联的核酸稳定性的方法及试剂盒 |
| IL327379A (en) * | 2023-09-26 | 2026-05-01 | Entrada Therapeutics Inc | Compounds and methods for skipping exon 50 in Duchenne muscular dystrophy |
| US20250325694A1 (en) * | 2024-04-03 | 2025-10-23 | Avidity Biosciences, Inc. | Antibody-oligonucleotide conjugate compositions and methods of inducing dmd exon 52 skipping |
| WO2026034445A1 (ja) * | 2024-08-05 | 2026-02-12 | 日本新薬株式会社 | ホスホロジアミデートモルフォリノオリゴ核酸（ｐｍｏ）とポリアニオンとを含む、ｐｍｏ複合体 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| JP2528107B2 (ja) | 1985-03-15 | 1996-08-28 | サマ−トン，ジエ−ムス | ポリヌクレオチド測定試薬と方法 |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| AU649074B2 (en) | 1990-10-12 | 1994-05-12 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Modified ribozymes |
| DE4216134A1 (de) | 1991-06-20 | 1992-12-24 | Europ Lab Molekularbiolog | Synthetische katalytische oligonukleotidstrukturen |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
| CA2192203A1 (en) | 1994-06-17 | 1995-12-28 | Werner Hofheinz | N,n'-bis(quinolin-4-yl)-diamine derivatives, their preparation and their use as antimalarials |
| US5716824A (en) | 1995-04-20 | 1998-02-10 | Ribozyme Pharmaceuticals, Inc. | 2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes) |
| US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
| AU1430097A (en) | 1996-01-16 | 1997-08-11 | Ribozyme Pharmaceuticals, Inc. | Synthesis of methoxy nucleosides and enzymatic nucleic acid molecules |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
| GB9816575D0 (en) | 1998-07-31 | 1998-09-30 | Zeneca Ltd | Novel compounds |
| CA2328356A1 (en) | 1999-12-22 | 2001-06-22 | Itty Atcravi | Recreational vehicles |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20040023220A1 (en) | 2002-07-23 | 2004-02-05 | Lawrence Greenfield | Integrated method for PCR cleanup and oligonucleotide removal |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| JP2008519863A (ja) | 2004-11-12 | 2008-06-12 | シアトル ジェネティクス インコーポレイティッド | Ｎ末端にアミノ安息香酸単位を有するオーリスタチン |
| LT2735568T (lt) | 2006-05-10 | 2017-11-27 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
| NZ584793A (en) * | 2007-10-26 | 2012-05-25 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| US20110065774A1 (en) | 2008-01-31 | 2011-03-17 | Alnylam Pharmaceuticals | Chemically modified oligonucleotides and uses thereof |
| WO2009117531A1 (en) | 2008-03-18 | 2009-09-24 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| US8575123B2 (en) * | 2008-04-11 | 2013-11-05 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| US20110130346A1 (en) * | 2008-05-30 | 2011-06-02 | Isis Innovation Limited | Peptide conjugates for delvery of biologically active compounds |
| EP3133160B1 (en) * | 2008-10-24 | 2018-12-12 | Sarepta Therapeutics, Inc. | Exon skipping compositions for dmd |
| BRPI0923225A2 (pt) | 2008-12-02 | 2016-10-04 | Chiralgen Ltd | metodo para sintese de acidos nucleicos modificados no atomo de fosforo |
| WO2010129666A1 (en) | 2009-05-05 | 2010-11-11 | Altermune Technologies, Llc | Chemically programmable immunity |
| HUE040445T2 (hu) | 2009-11-12 | 2019-03-28 | Univ Western Australia | Antiszensz molekulák és eljárások betegségek kezelésére |
| CN103068405A (zh) | 2010-04-15 | 2013-04-24 | 西雅图基因公司 | 靶向吡咯并苯并二氮杂卓结合物 |
| MX368648B (es) | 2010-04-15 | 2019-10-09 | Seattle Genetics Inc | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas. |
| KR101981705B1 (ko) | 2010-05-28 | 2019-05-24 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| JP2013531981A (ja) | 2010-06-11 | 2013-08-15 | アンチセンス・ファーマ・ゲーエムベーハー | 選択的オリゴヌクレオチド修飾の方法 |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| HUE031017T2 (en) * | 2011-04-01 | 2017-06-28 | Wyeth Llc | Antibody Drug Conjugates |
| CA2839593A1 (en) | 2011-07-15 | 2013-01-24 | Sarepta Therapeutics, Inc. | Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites |
| CN107365339A (zh) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| US10010623B2 (en) | 2012-02-16 | 2018-07-03 | Ucl Business Plc | Lysosome-cleavable linker |
| AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| CN104640572B (zh) | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物，偶联方法，及其用途 |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| DK2872147T3 (da) | 2012-07-13 | 2023-02-20 | Wave Life Sciences Ltd | Fremgangsmåde til fremstilling af kirale oligonukleotider |
| DK2839860T3 (da) | 2012-10-12 | 2019-06-17 | Medimmune Ltd | Pyrrolobenzodiazepiner og konjugater deraf |
| US10131682B2 (en) | 2012-11-24 | 2018-11-20 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules |
| KR20210132742A (ko) | 2012-12-21 | 2021-11-04 | 알트루바이오 인코퍼레이티드 | 친수성 자기-희생 링커 및 그것의 포합체 |
| US9481905B2 (en) | 2013-02-19 | 2016-11-01 | Orizhan Bioscience Limited | Method of using neutrilized DNA (N-DNA) as surface probe for high throughput detection platform |
| US9217148B2 (en) | 2013-03-14 | 2015-12-22 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
| EP3964237B1 (en) | 2013-03-15 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| HK1220154A1 (zh) * | 2013-03-15 | 2017-04-28 | Sarepta Therapeutics, Inc. | 改进的用於治疗肌营养不良的组合物 |
| EP2777714A1 (en) | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| US9295731B2 (en) | 2013-04-01 | 2016-03-29 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
| GB2529356B (en) | 2013-04-28 | 2020-12-23 | Genequantum Healthcare Co Ltd | Novel linkers, coupling intermediates, conjugates, preparation method and application thereof |
| US11229711B2 (en) | 2013-06-06 | 2022-01-25 | Magenta Therapeutics, Inc. | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
| WO2015038426A1 (en) | 2013-09-13 | 2015-03-19 | Asana Biosciences, Llc | Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof |
| AU2014337317A1 (en) | 2013-10-15 | 2016-09-15 | Sorrento Therapeutics Inc. | Drug-conjugates with a targeting molecule and two different drugs |
| PT3057585T (pt) | 2013-10-15 | 2020-10-21 | Seagen Inc | Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando |
| WO2015069587A2 (en) | 2013-11-06 | 2015-05-14 | Merck Sharp & Dohme Corp. | Peptide containing conjugates for dual molecular delivery of oligonucleotides |
| EP3094728B1 (en) | 2014-01-16 | 2022-03-09 | Wave Life Sciences Ltd. | Chiral design |
| PT3159409T (pt) * | 2014-06-17 | 2020-01-21 | Nippon Shinyaku Co Ltd | Ácido nucleico anti-sentido para utilização no tratamento da distrofia muscular de duchenne |
| KR102644053B1 (ko) * | 2015-05-19 | 2024-03-06 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 펩티드 올리고뉴클레오티드 콘주게이트 |
| JP2019516679A (ja) * | 2016-05-04 | 2019-06-20 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | 生物活性剤に関する方法および組成物 |
| KR20240172236A (ko) * | 2017-01-06 | 2024-12-09 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩티드 조성물 및 엑손 스키핑을 유도하는 방법 |
| US12071621B2 (en) * | 2022-04-05 | 2024-08-27 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping |
-
2018
- 2018-09-21 SG SG11202002517RA patent/SG11202002517RA/en unknown
- 2018-09-21 CN CN201880074378.2A patent/CN111770757A/zh active Pending
- 2018-09-21 KR KR1020207011734A patent/KR102805405B1/ko active Active
- 2018-09-21 KR KR1020257014783A patent/KR20250065737A/ko active Pending
- 2018-09-21 US US16/649,572 patent/US20200282074A1/en active Pending
- 2018-09-21 MX MX2020003130A patent/MX2020003130A/es unknown
- 2018-09-21 MA MA050269A patent/MA50269A/fr unknown
- 2018-09-21 CA CA3075425A patent/CA3075425A1/en active Pending
- 2018-09-21 EP EP18858928.7A patent/EP3684376A4/en not_active Withdrawn
- 2018-09-21 IL IL326219A patent/IL326219A/en unknown
- 2018-09-21 WO PCT/US2018/052289 patent/WO2019060775A1/en not_active Ceased
- 2018-09-21 AU AU2018335880A patent/AU2018335880B2/en active Active
- 2018-09-21 EP EP26171663.3A patent/EP4789717A2/en active Pending
- 2018-09-21 JP JP2020514269A patent/JP2020537497A/ja active Pending
-
2020
- 2020-03-19 IL IL273429A patent/IL273429B2/en unknown
-
2023
- 2023-07-20 JP JP2023118556A patent/JP7635307B2/ja active Active
-
2025
- 2025-01-17 US US19/031,269 patent/US20250170260A1/en active Pending
- 2025-02-12 JP JP2025021008A patent/JP7880452B2/ja active Active
- 2025-07-07 AU AU2025205176A patent/AU2025205176A1/en active Pending
- 2025-08-27 US US19/311,956 patent/US20250381286A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023130519A5 (enExample) | ||
| Sprengart et al. | The initiation of translation in E. coli: apparent base pairing between the 16srRNA and downstream sequences of the mRNA | |
| JP2020505330A5 (enExample) | ||
| ES2629747T3 (es) | Inducción de la omisión de exones en células eucarióticas | |
| US20250270555A1 (en) | Organic compositions to treat beta-catenin-related diseases | |
| Suter et al. | Double-target antisense U7 snRNAs promote efficient skipping of an aberrant exon in three human β-thalassemic mutations | |
| US20120190732A1 (en) | Multifunctional Aptamer-Nucleic Acid Nanostructures for Tumor-Targeted Killing | |
| US9631192B2 (en) | Auto-recognizing therapeutic RNA/DNA chimeric nanoparticles (NP) | |
| JP2017079759A5 (enExample) | ||
| JP2014518612A5 (enExample) | ||
| JP2017516461A (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| JP2022533358A5 (enExample) | ||
| JP2022518384A5 (enExample) | ||
| JP2022031642A (ja) | アンチセンスオリゴヌクレオチド | |
| US20210139893A1 (en) | G-quadruplex-containing antisense oligonucleotides | |
| CN119137272A (zh) | 血管紧张素原调节组合物和其使用方法 | |
| JP2022534086A5 (enExample) | ||
| US20220160870A1 (en) | Neoantigen engineering using splice modulating compounds | |
| KR102906801B1 (ko) | mRNA의 세포내 안정성과 생합성을 향상시키는 UTR 서열을 포함하는 구성물과 그 사용 | |
| JP2023516392A (ja) | アプタマーおよびその使用 | |
| CN117980479A (zh) | 用于治疗基于无义介导的rna衰变的病状和疾病的反义寡聚体 | |
| JP2023532536A (ja) | ｍｉＲＮＡ－４８５ハンチントン病の阻害剤 | |
| JP2022522898A (ja) | 分子の細胞内標的化 | |
| US20260015612A1 (en) | Novel staple nucleic acid | |
| JP2024529930A5 (enExample) |